Trials / Completed
CompletedNCT03020095
Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
Phase 2 Study To Investigate the Efficacy, Safety And Pharmacokinetics Of Ravidasvir In Combination With Ritonavir-boosted Danoprevir And Ribavirin In Treatment-naive Non-cirrhotic Taiwanese Patients Who Have Chronic Hepatitis C Genotype 1
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of Ravidasvir (ASC16) in combination with Ritonavir-boosted Danoprevir(ASC08) and Ribavirin in treatment-naive no-cirrhotic Taiwanese patients who have chronic hepatitis C genotype1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ravidasvir | Ravidasvir 200mg tablet administered orally once daily |
| DRUG | Danoprevir | Danoprevir 100mg tablet administered orally twice daily |
| DRUG | Ritonavir | Ritonavir 100mg tablet administered orally twice daily |
| DRUG | Ribavirin | Ribavirin(RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)administered orally |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2016-08-01
- Completion
- 2017-02-01
- First posted
- 2017-01-13
- Last updated
- 2020-10-22
- Results posted
- 2020-10-22
Source: ClinicalTrials.gov record NCT03020095. Inclusion in this directory is not an endorsement.